LHTC joins the EU-funded project VITAL: Virtual Twins as Tools for Personalized Clinical Care
VITAL, a groundbreaking Horizon Europe project, promises to revolutionize the diagnosis and treatment of cardiovascular diseases. As global healthcare moves towards personalized medicine, the project’s goal is to deliver a comprehensive and clinically validated digital twin platform.
The project will use physics-based and data-driven modeling of the physiology to help in the diagnosis and treatment of cardiovascular diseases such as heart failure and hypertension. The creation of virtual human twins, based on data from clinical exams and wearable sensors, can improve treatment outcomes and reduce healthcare costs.
The consortium is composed of leading universities across Europe (TU Delft, Maastricht University, University of Pisa, Jagiellonian University, Ghent University, EPFL), the UK (King’s College London and University College London) and New Zealand (Auckland Bioengineering Institute), 2 research centers (imec in the Netherlands and Austrian Institute of Technology), 2 SMEs (ELEM Biotech in Spain and WCR in the Netherlands) and Assistance Publique Hôpitaux de Paris, Europe’s largest hospital network. VITAL will run from 2024 until the end of 2029.
The LHTC is part of this initiative thanks to funding from the Swiss State Secretariat for Education, Research and lnnovation (SERI).
→ Stay up-to-date with the VITAL project by following the LinkedIn channel and visiting the project’s website!
→ To VITAL’s first press release
